Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 83

1.

Dupilumab facial redness: Positive effect of itraconazole.

de Beer FSA, Bakker DS, Haeck I, Ariens L, van der Schaft J, van Dijk MR, de Bruin-Weller MS.

JAAD Case Rep. 2019 Oct 22;5(10):888-891. doi: 10.1016/j.jdcr.2019.07.020. eCollection 2019 Oct. No abstract available.

2.

Dupilumab is very effective in a large cohort of difficult-to-treat adult atopic dermatitis patients: First clinical and biomarker results from the BioDay registry.

Ariëns LFM, van der Schaft J, Bakker DS, Balak D, Romeijn MLE, Kouwenhoven T, Kamsteeg M, Giovannone B, Drylewicz J, van Amerongen CCA, Delemarre EM, Knol EF, van Wijk F, Nierkens S, Thijs JL, Schuttelaar MLA, de Bruin-Weller MS.

Allergy. 2020 Jan;75(1):116-126. doi: 10.1111/all.14080. Epub 2019 Oct 31.

PMID:
31593343
3.

Early identification of atopic dermatitis patients in need of systemic immunosuppressive treatment.

Bakker DS, Drylewicz J, Nierkens S, Knol EF, Giovannone B, Delemarre EM, van der Schaft J, Balak DMW, de Bruin-Weller MS, Thijs JL.

Clin Exp Allergy. 2019 Dec;49(12):1641-1644. doi: 10.1111/cea.13495. Epub 2019 Sep 30. No abstract available.

PMID:
31520450
4.

Recurrence of conjunctival goblet cells after discontinuation of dupilumab in a patient with dupilumab-related conjunctivitis.

Voorberg AN, den Dunnen WFA, Wijdh RHJ, de Bruin-Weller MS, Schuttelaar MLA.

J Eur Acad Dermatol Venereol. 2019 Aug 29. doi: 10.1111/jdv.15914. [Epub ahead of print] No abstract available.

PMID:
31465590
5.

Effect of dupilumab on hand eczema in patients with atopic dermatitis: An observational study.

Oosterhaven JAF, Voorberg AN, Romeijn GLE, de Bruin-Weller MS, Schuttelaar MLA.

J Dermatol. 2019 Aug;46(8):680-685. doi: 10.1111/1346-8138.14982. Epub 2019 Jun 12.

6.

Dupilumab after the 2017 approval for the treatment of atopic dermatitis: what's new and what's next?

van der Schaft J, Thijs JL, de Bruin-Weller MS, Balak DMW.

Curr Opin Allergy Clin Immunol. 2019 Aug;19(4):341-349. doi: 10.1097/ACI.0000000000000551.

PMID:
31145194
7.

Conjunctivitis in atopic dermatitis patients with and without dupilumab therapy - international eczema council survey and opinion.

Thyssen JP, de Bruin-Weller MS, Paller AS, Leshem YA, Vestergaard C, Deleuran M, Drucker AM, Foelster-Holst R, Traidl-Hoffmann C, Eyerich K, Taieb A, Su JC, Bieber T, Cork MJ, Eichenfield LF, Guttman-Yassky E, Wollenberg A.

J Eur Acad Dermatol Venereol. 2019 Jul;33(7):1224-1231. doi: 10.1111/jdv.15608. Epub 2019 May 6.

8.

Biomarkers detected in dried blood spots from atopic dermatitis patients strongly correlate with disease severity.

Thijs JL, Fiechter R, Giovannone B, de Bruin-Weller MS, Knol EF, Bruijnzeel-Koomen CAFM, Drylewicz J, Nierkens S, Hijnen D.

Allergy. 2019 Nov;74(11):2240-2243. doi: 10.1111/all.13839. Epub 2019 Aug 5. No abstract available.

PMID:
31016745
9.

[Ocular symptoms associated with dupilumab in atopic dermatitis].

Voorberg AN, Oosterhaven JAF, Wijdh RHJ, de Bruin-Weller MS, Schuttelaar MLA.

Ned Tijdschr Geneeskd. 2019 Mar 21;163. pii: D3227. Dutch.

PMID:
30945835
10.

Towards personalized treatment in atopic dermatitis.

van der Schaft J, Thijs JL, Garritsen FM, Balak D, de Bruin-Weller MS.

Expert Opin Biol Ther. 2019 May;19(5):469-476. doi: 10.1080/14712598.2019.1583204. Epub 2019 Feb 26.

PMID:
30768375
11.

Goblet cell scarcity and conjunctival inflammation during treatment with dupilumab in patients with atopic dermatitis.

Bakker DS, Ariens LFM, van Luijk C, van der Schaft J, Thijs JL, Schuttelaar MLA, van Wijk F, Knol EF, Balak DMW, van Dijk MR, de Bruin-Weller MS.

Br J Dermatol. 2019 May;180(5):1248-1249. doi: 10.1111/bjd.17538. Epub 2019 Feb 4. No abstract available.

12.

EASI p-EASI: Predicting disease severity in atopic dermatitis patients treated with cyclosporin A.

Thijs JL, Drylewicz J, Bruijnzeel-Koomen CAFM, Giovannone B, Knol EF, de Bruin-Weller MS, Nierkens S, Hijnen D.

Allergy. 2019 Mar;74(3):613-617. doi: 10.1111/all.13651. Epub 2018 Dec 16. No abstract available.

PMID:
30368864
13.

Dupilumab in atopic dermatitis: rationale, latest evidence and place in therapy.

Ariëns LFM, Bakker DS, van der Schaft J, Garritsen FM, Thijs JL, de Bruin-Weller MS.

Ther Adv Chronic Dis. 2018 May 11;9(9):159-170. doi: 10.1177/2040622318773686. eCollection 2018 Sep. Review.

14.

Successful Treatment with Dupilumab in a Patient with Severe, Difficult to Treat Atopic Dermatitis: Beware of Symptomatic Adrenal Insufficiency due to Abrupt Discontinuation of Potent Topical Corticosteroids.

Ariëns LFM, van der Schaft J, Stades AME, van de Woestijne AA, De Bruin-Weller MS.

Acta Derm Venereol. 2018 Jun 8;98(6):601-602. doi: 10.2340/00015555-2936. No abstract available.

15.

Patterns of topical corticosteroids prescriptions in children with asthma.

Arabkhazaeli A, Vijverberg SJH, van der Lee M, van der Ent CK, Bruijnzeel-Koomen CA, de Bruin-Weller MS, Raaijmakers JA, Maitland-van der Zee AH.

Pediatr Dermatol. 2018 May;35(3):378-383. doi: 10.1111/pde.13455. Epub 2018 Mar 24.

PMID:
29573273
16.

Lymphopenia in atopic dermatitis patients treated with oral immunosuppressive drugs.

Bakker DS, Garritsen FM, Leavis HL, van der Schaft J, Bruijnzeel-Koomen CAFM, van den Broek MPH, de Bruin-Weller MS.

J Dermatolog Treat. 2018 Nov;29(7):682-687. doi: 10.1080/09546634.2018.1451619. Epub 2018 Mar 28.

PMID:
29526121
17.

Use of oral immunosuppressive drugs in the treatment of atopic dermatitis in the Netherlands.

Garritsen FM, van den Heuvel JM, Bruijnzeel-Koomen CAFM, Maitland-van der Zee AH, van den Broek MPH, de Bruin-Weller MS.

J Eur Acad Dermatol Venereol. 2018 Aug;32(8):1336-1342. doi: 10.1111/jdv.14896.

PMID:
29485224
18.

Serum biomarker profiles suggest that atopic dermatitis is a systemic disease.

Thijs JL, Strickland I, Bruijnzeel-Koomen CAFM, Nierkens S, Giovannone B, Knol EF, Csomor E, Sellman BR, Mustelin T, Sleeman MA, de Bruin-Weller MS, Herath A, Drylewicz J, May RD, Hijnen D.

J Allergy Clin Immunol. 2018 Apr;141(4):1523-1526. doi: 10.1016/j.jaci.2017.12.991. Epub 2018 Feb 2. No abstract available.

PMID:
29410314
19.

Initial Results of Secukinumab Drug Survival in Patients with Psoriasis: A Multicentre Daily Practice Cohort Study.

van den Reek JMPA, van Vugt LJ, van Doorn MBA, van der Kraaij GE, de Kort WJA, Lucker GPH, Horvath B, Njoo MD, Bovenschen HJ, Ossenkoppele PM, De Bruin-Weller MS, de Groot M, Mommers R, Prevoo RLMA, van de Kerkhof PCM, Spuls PI, Kievit W, de Jong EMGJ.

Acta Derm Venereol. 2018 Jul 11;98(7):648-654. doi: 10.2340/00015555-2900.

20.

Allopurinol Co-prescription Improves the Outcome of Azathioprine Treatment in Chronic Eczema.

Garritsen FM, van der Schaft J, de Graaf M, Hijnen DJ, Bruijnzeel-Koomen CAF, van den Broek MPH, De Bruin-Weller MS.

Acta Derm Venereol. 2018 Mar 13;98(3):373-375. doi: 10.2340/00015555-2839. No abstract available.

21.

Is there an increased risk of cervical neoplasia in atopic dermatitis patients treated with oral immunosuppressive drugs?

Garritsen FM, Verheijen RHM, Gerestein CG, van Zuilen AD, Oosterhaven JAF, van Dijk M, Bruijnzeel-Koomen CAF, Schuttelaar ML, de Bruin-Weller MS.

J Eur Acad Dermatol Venereol. 2018 Feb;32(2):271-275. doi: 10.1111/jdv.14593. Epub 2017 Oct 10.

PMID:
28925576
22.

Thiopurine metabolite levels in patients with atopic dermatitis and/or chronic hand/foot eczema treated with azathioprine.

Garritsen FM, van der Schaft J, Bruijnzeel-Koomen CAF, van Schaik RH, de Graaf M, van den Broek MPH, de Bruin-Weller MS.

J Dermatolog Treat. 2018 Jun;29(4):375-382. doi: 10.1080/09546634.2017.1373738. Epub 2017 Sep 26.

PMID:
28914560
23.

Barriers and Facilitators to eHealth Use in Daily Practice: Perspectives of Patients and Professionals in Dermatology.

Ariens LF, Schussler-Raymakers FM, Frima C, Flinterman A, Hamminga E, Arents BW, Bruijnzeel-Koomen CA, de Bruin-Weller MS, van Os-Medendorp H.

J Med Internet Res. 2017 Sep 5;19(9):e300. doi: 10.2196/jmir.7512.

24.

Use of systemic corticosteroids for atopic dermatitis: International Eczema Council consensus statement.

Drucker AM, Eyerich K, de Bruin-Weller MS, Thyssen JP, Spuls PI, Irvine AD, Girolomoni G, Dhar S, Flohr C, Murrell DF, Paller AS, Guttman-Yassky E.

Br J Dermatol. 2018 Mar;178(3):768-775. doi: 10.1111/bjd.15928. Epub 2018 Jan 28.

25.

EASI p-EASI: Utilizing a combination of serum biomarkers offers an objective measurement tool for disease severity in atopic dermatitis patients.

Thijs JL, Drylewicz J, Fiechter R, Strickland I, Sleeman MA, Herath A, May RD, Bruijnzeel-Koomen CAFM, Knol EF, Giovannone B, de Bruin-Weller MS, Nierkens S, Hijnen DJ.

J Allergy Clin Immunol. 2017 Dec;140(6):1703-1705. doi: 10.1016/j.jaci.2017.06.046. Epub 2017 Aug 16. No abstract available.

PMID:
28823810
26.

Erratum to: Progressive multifocal leukoencephalopathy in patients treated with fumaric acid esters: a review of 19 cases.

Gieselbach RJ, Muller-Hansma AH, Wijburg MT, de Bruin-Weller MS, van Oosten BW, Nieuwkamp DJ, Coenjaerts FE, Wattjes MP, Murk JL.

J Neurol. 2017 Aug;264(8):1833-1836. doi: 10.1007/s00415-017-8557-1. No abstract available.

PMID:
28711999
27.

Atopic dermatitis characteristics and medication-use patterns in school-age children with AD and asthma symptoms.

van der Lee M, Arabkhazaeli A, van Erp FC, Raaijmakers JA, van der Ent CK, Bruijnzeel-Koomen CAFM, de Bruin-Weller MS, Vijverberg SJH, Maitland-van der Zee AH.

Clin Exp Dermatol. 2017 Jul;42(5):503-508. doi: 10.1111/ced.13111. Epub 2017 Jun 6.

PMID:
28585727
28.

Progressive multifocal leukoencephalopathy in patients treated with fumaric acid esters: a review of 19 cases.

Gieselbach RJ, Muller-Hansma AH, Wijburg MT, de Bruin-Weller MS, van Oosten BW, Nieuwkamp DJ, Coenjaerts FE, Wattjes MP, Murk JL.

J Neurol. 2017 Jun;264(6):1155-1164. doi: 10.1007/s00415-017-8509-9. Epub 2017 May 23. Review. Erratum in: J Neurol. 2017 Jul 15;:.

PMID:
28536921
29.

Pregnancy and fetal outcomes after paternal exposure to azathioprine, methotrexate or mycophenolic acid: a critically appraised topic.

Garritsen FM, van den Broek MPH, van Zuilen AD, Fidder HH, de Bruin-Weller MS, Spuls PI.

Br J Dermatol. 2017 Apr;176(4):866-877. doi: 10.1111/bjd.15320. Review. No abstract available.

PMID:
28418137
30.

Moving toward endotypes in atopic dermatitis: Identification of patient clusters based on serum biomarker analysis.

Thijs JL, Strickland I, Bruijnzeel-Koomen CAFM, Nierkens S, Giovannone B, Csomor E, Sellman BR, Mustelin T, Sleeman MA, de Bruin-Weller MS, Herath A, Drylewicz J, May RD, Hijnen D.

J Allergy Clin Immunol. 2017 Sep;140(3):730-737. doi: 10.1016/j.jaci.2017.03.023. Epub 2017 Apr 13. Erratum in: J Allergy Clin Immunol. 2018 Aug;142(2):714.

PMID:
28412391
31.

Multiplex platform technology and bioinformatics are essential for development of biomarkers in atopic dermatitis.

Thijs JL, Herath A, de Bruin-Weller MS, Hijnen D.

J Allergy Clin Immunol. 2017 Mar;139(3):1065. doi: 10.1016/j.jaci.2016.08.023. Epub 2016 Oct 26. No abstract available.

PMID:
28341480
32.

Immunoglobulin free light chains in adult atopic dermatitis patients do not correlate with disease severity.

Thijs JL, Knipping K, Bruijnzeel-Koomen CA, Garssen J, de Bruin-Weller MS, Hijnen DJ.

Clin Transl Allergy. 2016 Dec 6;6:44. eCollection 2016.

33.

Current and Future Biomarkers in Atopic Dermatitis.

Thijs JL, de Bruin-Weller MS, Hijnen D.

Immunol Allergy Clin North Am. 2017 Feb;37(1):51-61. doi: 10.1016/j.iac.2016.08.008. Epub 2016 Oct 28. Review.

PMID:
27886910
34.

Serum vitamin D status in adult patients with atopic dermatitis: Recommendations for daily practice.

van der Schaft J, Ariens LF, Bruijnzeel-Koomen CA, de Bruin-Weller MS.

J Am Acad Dermatol. 2016 Dec;75(6):1257-1259. doi: 10.1016/j.jaad.2016.07.035. No abstract available.

PMID:
27846950
35.

Predicting therapy response to mycophenolic acid using UGT1A9 genotyping: towards personalized medicine in atopic dermatitis.

Thijs JL, Van Der Geest BAM, Van Der Schaft J, Van Den Broek MP, Van Seggelen WO, Bruijnzeel-Koomen CAF, Hijnen DJ, Van Schaik RH, De Bruin-Weller MS.

J Dermatolog Treat. 2017 May;28(3):242-245. doi: 10.1080/09546634.2016.1227420. Epub 2016 Sep 13.

PMID:
27549213
36.

Is There an Additional Value of Inpatient Treatment for Patients with Atopic Dermatitis?

van der Schaft J, Keijzer WW, Sanders KJ, de Groot JJ, van den Bersselaar DL, van Os-Medendorp H, van Doorn-Op den Akker MM, Bruijnzeel-Koomen CA, de Bruin-Weller MS.

Acta Derm Venereol. 2016 Aug 23;96(6):797-801. doi: 10.2340/00015555-2410.

37.

Drug survival for azathioprine and enteric-coated mycophenolate sodium in a long-term daily practice cohort of adult patients with atopic dermatitis.

van der Schaft J, Politiek K, van den Reek JM, Kievit W, de Jong EM, Bruijnzeel-Koomen CA, Schuttelaar ML, de Bruin-Weller MS.

Br J Dermatol. 2016 Jul;175(1):199-202. doi: 10.1111/bjd.14398. Epub 2016 Apr 17. No abstract available.

PMID:
26785104
38.

Rush immunotherapy for wasp venom allergy seems safe and effective in patients with mastocytosis.

Verburg M, Oldhoff JM, Klemans RJ, Lahey-de Boer A, de Bruin-Weller MS, Röckmann H, Sanders C, Bruijnzeel-Koomen CA, Pasmans SG, Knulst AC.

Eur Ann Allergy Clin Immunol. 2015 Nov;47(6):192-6.

39.

First experience with extended release tacrolimus in the treatment of adult patients with severe, difficult to treat atopic dermatitis: Clinical efficacy, safety and dose finding.

van der Schaft J, van Schaik RH, van Zuilen AD, Hijnen DJ, Berg MT, van den Broek MP, Bruijnzeel-Koomen CA, de Bruin-Weller MS.

J Dermatol Sci. 2016 Jan;81(1):66-8. doi: 10.1016/j.jdermsci.2015.10.013. Epub 2015 Oct 28. No abstract available.

PMID:
26547110
40.

Drug survival of methotrexate treatment in hand eczema patients: results from a retrospective daily practice study.

Politiek K, van der Schaft J, Christoffers WA, Coenraads PJ, van den Reek JM, de Jong EM, de Bruin-Weller MS, Schuttelaar ML.

J Eur Acad Dermatol Venereol. 2016 Aug;30(8):1405-7. doi: 10.1111/jdv.13253. Epub 2015 Sep 14. No abstract available.

PMID:
26369396
41.

Increased liver enzyme levels during azathioprine treatment: beware of concomitant use of proton pump inhibitors.

van der Schaft J, van Schaik RH, van den Broek MP, Bruijnzeel-Koomen CA, de Bruin-Weller MS.

Br J Dermatol. 2015 Nov;173(5):1338-9. doi: 10.1111/bjd.14006. Epub 2015 Oct 13. No abstract available.

PMID:
26139089
42.

Drug survival for methotrexate in a daily practice cohort of adult patients with severe atopic dermatitis.

Politiek K, van der Schaft J, Coenraads PJ, de Bruin-Weller MS, Schuttelaar ML.

Br J Dermatol. 2016 Jan;174(1):201-3. doi: 10.1111/bjd.13961. Epub 2015 Nov 8. No abstract available.

PMID:
26111229
43.

Serum creatinine levels during and after long-term treatment with cyclosporine A in patients with severe atopic dermatitis.

van der Schaft J, van Zuilen AD, Deinum J, Bruijnzeel-Koomen CA, de Bruin-Weller MS.

Acta Derm Venereol. 2015 Nov;95(8):963-7. doi: 10.2340/00015555-2125.

44.

Ten years experience with oral immunosuppressive treatment in adult patients with atopic dermatitis in two academic centres.

Garritsen FM, Roekevisch E, van der Schaft J, Deinum J, Spuls PI, de Bruin-Weller MS.

J Eur Acad Dermatol Venereol. 2015 Oct;29(10):1905-12. doi: 10.1111/jdv.13064. Epub 2015 Mar 9.

PMID:
25752497
45.

Drug survival of cyclosporine in the treatment of hand eczema: a multicentre, daily use study.

Christoffers WA, Politiek K, Coenraads PJ, van der Schaft J, de Bruin-Weller MS, Schuttelaar ML.

J Eur Acad Dermatol Venereol. 2016 Jan;30(1):63-6. doi: 10.1111/jdv.13057. Epub 2015 Mar 2.

PMID:
25731072
46.

Drug survival for ciclosporin A in a long-term daily practice cohort of adult patients with atopic dermatitis.

van der Schaft J, Politiek K, van den Reek JMPA, Christoffers WA, Kievit W, de Jong EMGJ, Bruijnzeel-Koomen CAFM, Schuttelaar MLA, de Bruin-Weller MS.

Br J Dermatol. 2015 Jun;172(6):1621-1627. doi: 10.1111/bjd.13730. Epub 2015 May 11.

PMID:
25683671
47.

A panel of biomarkers for disease severity in atopic dermatitis.

Thijs JL, Nierkens S, Herath A, Bruijnzeel-Koomen CA, Knol EF, Giovannone B, de Bruin-Weller MS, Hijnen D.

Clin Exp Allergy. 2015 Mar;45(3):698-701. doi: 10.1111/cea.12486. No abstract available.

PMID:
25599896
48.

Food allergen sensitization pattern in adults in relation to severity of atopic dermatitis.

Röckmann H, van Geel MJ, Knulst AC, Huiskes J, Bruijnzeel-Koomen CA, de Bruin-Weller MS.

Clin Transl Allergy. 2014 Mar 28;4(1):9. doi: 10.1186/2045-7022-4-9.

49.

Evaluation of the adult patient with atopic dermatitis.

de Bruin Weller MS, Rockmann H, Knulst AC, Bruijnzeel-Koomen CA.

Clin Exp Allergy. 2013 Mar;43(3):279-91. doi: 10.1111/cea.12030. Review.

PMID:
23414536
50.

Treatment of atopic keratoconjunctivitis in patients with atopic dermatitis: is ocular application of tacrolimus an option?

Westland T, de Bruin-Weller MS, Van der Lelij A.

J Eur Acad Dermatol Venereol. 2013 Sep;27(9):1187-9. doi: 10.1111/jdv.12022. Epub 2012 Oct 26. No abstract available.

PMID:
23106347

Supplemental Content

Loading ...
Support Center